• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bone marrow transplantation >Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis.
【24h】

Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis.

机译：Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis.

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for patients with malignant and benign hematologic conditions. Graft-versus-host disease (GVHD) is a known complication of allo-HCT that results in significant morbidity and mortality. A common GVHD prophylaxis strategy combines a calcineurin inhibitor with methotrexate. When mucositis and organ toxicity develop, the day +11 dose is frequently omitted to limit further organ damage. The potential impact of this practice on allo-HCT outcomes is unclear as published data show conflicting results. Thus, we performed a systematic review/meta-analysis of the available literature to assess the impact of omitting day +11 methotrexate on allo-HCT recipients. Data were extracted in relation to benefits (overall survival [OS], progression-free survival [PFS]) and harms (acute and chronic GVHD, non-relapse mortality [NRM], and relapse). Pooled OS rate favored those who received day +11 methotrexate vs. those who did not (HR?=?1.21; 95% CI?=?1.02-1.43; p?=?0.03). There was no significant difference in pooled rates of PFS (HR?=?0.96; 95% CI?=?0.60-1.52; p?=?0.85), acute GVHD (HR?=?1.03; 95% CI?=?0.35-2.98; p?=?0.96), chronic GVHD (HR?=?0.83; 95% CI?=?0.44-1.57; p?=?0.57), NRM (HR?=?0.86; 95% CI?=?0.67-1.11; p?=?0.25), and relapse (HR?=?0.97; 95% CI?=?0.75-1.26; p?=?0.83) between the two groups. Large prospective multicenter studies are needed to better define the significance of day +11 methotrexate omission.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号